Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era

View through CrossRef
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option. Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent. She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.5 years from diagnosis. Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol. Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.
Title: Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era
Description:
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option.
Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent.
She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.
5 years from diagnosis.
Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol.
Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.

Related Results

Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Abstract Introduction: Gliosarcoma (GSM) is a rare, aggressive primary CNS tumor and a histopathological variant of glioblastoma, characterized by both glial and sarcomatou...
Fulvestrant Enhances Temozolomide Effectiveness Against Glioblastoma: Insights from a Preclinical Study
Fulvestrant Enhances Temozolomide Effectiveness Against Glioblastoma: Insights from a Preclinical Study
Introduction: Glioblastomas (GBM) are among the most aggressive primary brain tumors, as they are characterized by a median survival of less than 15 months. The...
EXTH-23. COMBINED EFFECTS OF NICLOSAMIDE AND TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES
EXTH-23. COMBINED EFFECTS OF NICLOSAMIDE AND TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES
Abstract PURPOSE Glioblastoma (GBM) is the most aggressive type of brain tumor and has poor survival outcomes, even after a comb...
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma
Objective We aimed to characterise the magnetic resonance imaging (MRI) features of a case series of primary gliosarcoma, with the inclusion of diffusion-weight...
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Nanoparticles are currently used as drug carriers. Temozolomide is an antineoplastic drug for tumor in central nervous system. It presents a half‐life of 1.8 hours. For this reason...
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide. Suppression of hypoxia-inducible factor 1α has been shown...
Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review
Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review
Objective/Introduction: Although a critical chemotherapeutic, temozolomide's optimal regimen for 2016 World Health Organization (WHO) Grade II gliomas remains elusive, hence there ...
COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
Abstract Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We ...

Back to Top